StocksFundsScreenerSectorsWatchlists
ESPR

ESPR - Esperion Therapeutics Inc Stock Price, Fair Value and News

2.55USD-0.07 (-2.67%)Delayed as of 28 Mar 2024, 11:09 am ET

Market Summary

ESPR
USD2.55-0.07
Delayedas of 28 Mar 2024, 11:09 am
-2.67%

ESPR Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

ESPR Stock Price

View Fullscreen

ESPR RSI Chart

ESPR Valuation

Market Cap

484.8M

Price/Earnings (Trailing)

-2.32

Price/Sales (Trailing)

4.17

Price/Free Cashflow

-3.58

ESPR Price/Sales (Trailing)

ESPR Profitability

Return on Equity

-18.39%

Return on Assets

-101.68%

Free Cashflow Yield

-27.94%

ESPR Fundamentals

ESPR Revenue

Revenue (TTM)

116.3M

Rev. Growth (Yr)

71.38%

Rev. Growth (Qtr)

-5.06%

ESPR Earnings

Earnings (TTM)

-209.2M

Earnings Growth (Yr)

-1.54%

Earnings Growth (Qtr)

-36.59%

Breaking Down ESPR Revenue

52 Week Range

0.852.71
(Low)(High)

Last 7 days

10.6%

Last 30 days

-14.9%

Last 90 days

-3.0%

Trailing 12 Months

47.7%

How does ESPR drawdown profile look like?

ESPR Financial Health

Current Ratio

1.29

Debt/Equity

1e-4

Debt/Cashflow

-967.76

ESPR Investor Care

Shares Dilution (1Y)

141.67%

Diluted EPS (TTM)

-2.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202381.0M87.9M102.9M116.3M
202289.3M67.5M72.1M75.5M
2021233.7M62.1M72.7M78.4M
2020168.2M188.0M207.8M227.5M
2019000148.4M

Tracking the Latest Insider Buys and Sells of Esperion Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 14, 2024
warren eric
acquired
-
-
100,000
chief commercial officer
Mar 14, 2024
foody joanne m.
acquired
-
-
150,000
chief medical officer
Mar 14, 2024
halladay benjamin
acquired
-
-
170,000
chief financial officer
Mar 14, 2024
koenig sheldon l.
acquired
-
-
454,000
president and ceo
Mar 14, 2024
looker benjamin
acquired
-
-
100,000
general counsel
Sep 20, 2023
warren eric
sold
-923
1.245
-742
chief commercial officer
Aug 18, 2023
warren eric
sold
-343
1.414
-243
chief commercial officer
Jul 19, 2023
warren eric
sold
-168
1.585
-106
chief commercial officer
Jun 21, 2023
warren eric
sold
-894
1.483
-603
chief commercial officer
Jun 15, 2023
fischer seth h. z.
acquired
-
-
5,150
-

1–10 of 50

Which funds bought or sold ESPR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
8.36
10,715,300
15,361,900
-%
Mar 08, 2024
TRUST CO OF VERMONT
sold off
-100
-294
-
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
79.68
5,169,800
6,323,260
-%
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-178,000
-
-%
Feb 23, 2024
Chicago Partners Investment Group LLC
reduced
-48.93
7,120
30,584
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
71,000
106,000
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
sold off
-100
-7.00
-
-%
Feb 16, 2024
O'Dell Group, LLC
new
-
13,455
13,455
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
1.03
2,279,000
3,373,000
0.28%
Feb 15, 2024
BARCLAYS PLC
added
36.07
275,000
362,000
-%

1–10 of 34

Are Funds Buying or Selling ESPR?

Are funds buying ESPR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ESPR
No. of Funds

Unveiling Esperion Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
two seas capital lp
6.8%
7,686,120
SC 13G/A
Feb 14, 2024
deep track capital, lp
0%
0
SC 13G/A
Feb 14, 2024
cvi investments, inc.
0%
0
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
0.1%
4,800
SC 13G/A
Feb 13, 2024
vanguard group inc
4.52%
5,137,750
SC 13G/A
Feb 09, 2024
wasatch advisors lp
-
0
SC 13G/A
Jan 24, 2024
bb biotech ag
5.1%
9,194,064
SC 13G/A
Jan 24, 2024
bb biotech ag
3.7%
4,194,064
SC 13G/A
Jan 17, 2024
millennium management llc
3.2%
3,643,951
SC 13G/A
Jan 03, 2024
meditor group ltd
3.3%
3,791,300
SC 13G/A

Recent SEC filings of Esperion Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 15, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading
Feb 27, 2024
10-K
Annual Report
Feb 27, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Esperion Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
380.6B
85.2B
-0.84% 1.87%
10.83
4.47
6.46% 95.94%
333.8B
60.1B
-3.08% 18.97%
914.53
5.55
1.40% -97.49%
156.9B
46.5B
-0.94% -29.07%
-113.02
3.37
42.59% -114.62%
153.4B
28.2B
-2.65% 20.18%
22.84
5.44
7.09% 2.52%
91.0B
27.1B
1.44% -6.08%
16.06
3.35
-0.60% 23.36%
16.2B
15.8B
6.68% 47.26%
-28.08
1.02
6.17% 76.47%
MID-CAP
4.6B
1.7B
-15.20% 8.04%
12.8
2.74
49.61% 324.78%
4.3B
4.7B
-2.22% -15.29%
-335.7
0.92
4.58% 90.97%
3.8B
8.8B
12.34% 25.79%
-6.47
0.44
7.79% -163.11%
2.1B
644.4M
-19.16% 20.49%
15.22
3.25
29.14% 50.51%
SMALL-CAP
1.8B
700.5M
20.31% -
-1.29
2.63
16.26% -147.49%
24.2M
70.0M
1.33% -38.14%
0.35
0.34
-19.54% 888.31%
18.7M
-
-10.40% 69.70%
-1.01
0.22
2882.68% -138.52%
14.8M
111.1M
-18.24% -6.20%
-0.93
0.13
-10.43% 84.90%
929.3K
20.0M
-54.17% -94.76%
-0.07
0.05
137.71% 66.04%

Esperion Therapeutics Inc News

Latest updates
Defense World9 hours ago
Yahoo Finance15 Feb 202408:00 am

Esperion Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-5.1%32.0034.0026.0024.0019.0019.0019.0019.0015.0014.0041.008.0010.004.002121071.001.001.00145
Operating Expenses21.3%75.0062.0063.0073.0061.0061.0071.0062.0071.0070.0073.0091.0010584.0083.0076.0060.0067.0056.0058.00
  S&GA Expenses36.7%45.0033.0034.0030.0024.0025.0030.0030.0038.0039.0046.0061.0062.0049.0048.0042.0022.0018.0013.0012.00
Interest Expenses0.4%15.0015.0015.0014.0014.0014.0014.0014.0013.0014.0011.008.009.005.005.004.004.004.00--
Net Income-36.6%-56.34-41.25-49.93-61.72-55.49-55.12-66.32-56.73-65.12-69.39-43.67-90.93-104-85.44125-78.25-61.95-68.38-54.2287.00
Net Income Margin11.2%-1.80*-2.03*-2.53*-2.95*-3.10*-3.38*-3.82*-2.63*-3.43*-4.24*-5.23*---------
Free Cashflow-91.8%-37.06-19.32-24.75-54.36-42.47-42.83-50.53-38.99-57.71-69.17-47.87---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-7.0%206221235252248313304343382225280279353251330180214255309236143
  Current Assets-7.9%201218232251247262252291329171275273346243321173212253307235143
    Cash Equivalents-28.4%82.0011513814512515912315025910421921830521629814916721227417537.00
  Inventory27.6%66.0051.0046.0039.0035.0030.0029.0036.0034.0034.0024.0020.0016.009.008.002.00-----
  Net PPE-100.0%-0.000.000.000.000.000.001.001.001.001.001.001.001.002.001.001.001.001.000.001.00
Liabilities4.7%66163160758157260759659257958858554844924224523019418717961.0064.00
  Current Liabilities13.4%15613810795.0092.0082.0082.0079.0073.0078.0083.0098.0094.0076.0084.0073.0066.0058.0054.0060.0064.00
Shareholder's Equity--------------9.0085.00-20.0069.0012917579.00
  Retained Earnings-3.8%-1,549-1,492-1,451-1,401-1,340-1,284-1,229-1,163-1,106-1,041-971-928-838-734-648-773-695-633-564-510-598
  Additional Paid-In Capital1.0%1,1491,1381,1351,1271,0711,045993969964734723714798743734723715702694686678
Shares Outstanding3.1%10310094.0078.0066.0064.0063.0061.0029.0026.0026.00----------
Float---143---422---593---1,410---1,090--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-91.8%-37,056-19,325-24,750-54,356-42,472-42,833-50,532-38,990-57,706-69,169-47,866-89,068-68,550-86,671139,391-69,347-49,994-58,029-54,00991,691-28,692
  Share Based Compensation-1.8%2,9202,9753,1602,9033,7153,5373,5274,4364,4745,4978,5845,7516,6737,2647,3957,0536,3586,3276,5636,6366,829
Cashflow From Investing---17,50025,000-11,79433,0005,000-18,102-50,484----12,6762,3335,11026,589-2,868-5,31326,71645,69638,568
Cashflow From Financing203.7%4,471-4,31280949,492-30,35846,29218,108-1,436213,4103,65549,1132,045170,4401,5973,67426,0147,014976126,5361,669342

ESPR Income Statement

2023-12-31
Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues:  
Total Revenues$ 116,334$ 75,475
Operating expenses:  
Cost of goods sold43,26726,967
Research and development86,107118,927
Selling, general and administrative142,523109,082
Total operating expenses271,897254,976
Loss from operations(155,563)(179,501)
Interest expense(58,976)(56,810)
Other income, net5,2912,652
Net loss$ (209,248)$ (233,659)
Net loss per common share - basic (in dollars per share)$ (2.03)$ (3.52)
Net loss per common share - diluted (in dollars per share)$ (2.03)$ (3.52)
Weighted-average shares outstanding - basic (in shares)103,106,61666,407,242
Weighted-average shares outstanding - diluted (in shares)103,106,61666,407,242
Other comprehensive (loss) gain:  
Unrealized gain on investments$ 2$ 29
Total comprehensive loss(209,246)(233,630)
Product  
Revenues:  
Total Revenues78,33555,863
Collaboration Revenue  
Revenues:  
Total Revenues$ 37,999$ 19,612

ESPR Balance Sheet

2023-12-31
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 82,248$ 124,775
Short-term investments042,086
Accounts receivable48,49433,729
Inventories, net65,62335,201
Prepaid clinical development costs1931,026
Other prepaid and current assets4,5079,866
Total current assets201,065246,683
Noncurrent assets:  
Property and equipment, net0164
Right of use operating lease assets4,6751,036
Intangible assets5656
Total assets205,796247,939
Current liabilities:  
Accounts payable31,71823,040
Accrued clinical development costs3,4415,426
Accrued legal fees34,28421,987
Other accrued liabilities24,99813,204
Revenue interest liability34,82824,760
Deferred revenue from collaborations25,4023,507
Operating lease liabilities1,553384
Total current liabilities156,22492,308
Convertible notes, net of issuance costs261,596259,899
Revenue interest liability239,950218,845
Operating lease liabilities3,020665
Total liabilities660,790571,717
Commitments and contingencies (Note 5)
Stockholders’ (deficit) equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and December 31, 202200
Common stock, $0.001 par value; 480,000,000 shares authorized as of December 31, 2023 and 240,000,000 shares authorized as of December 31, 2022; 120,204,513 shares issued at December 31, 2023 and 76,564,396 shares issued at December 31, 202211875
Additional paid-in capital1,149,1701,071,183
Treasury stock, at cost; 1,994,198 shares at December 31, 2023 and December 31, 2022(54,998)(54,998)
Accumulated other comprehensive loss0(2)
Accumulated deficit(1,549,284)(1,340,036)
Total stockholders' deficit(454,994)(323,778)
Total liabilities and stockholders' deficit$ 205,796$ 247,939
ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
 CEO
 WEBSITEwww.esperion.com
 EMPLOYEES199

Esperion Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Esperion Therapeutics Inc? What does ESPR stand for in stocks?

ESPR is the stock ticker symbol of Esperion Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Esperion Therapeutics Inc (ESPR)?

As of Wed Mar 27 2024, market cap of Esperion Therapeutics Inc is 484.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ESPR stock?

You can check ESPR's fair value in chart for subscribers.

What is the fair value of ESPR stock?

You can check ESPR's fair value in chart for subscribers. The fair value of Esperion Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Esperion Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ESPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Esperion Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ESPR is over valued or under valued. Whether Esperion Therapeutics Inc is cheap or expensive depends on the assumptions which impact Esperion Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ESPR.

What is Esperion Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, ESPR's PE ratio (Price to Earnings) is -2.32 and Price to Sales (PS) ratio is 4.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ESPR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Esperion Therapeutics Inc's stock?

In the past 10 years, Esperion Therapeutics Inc has provided -0.169 (multiply by 100 for percentage) rate of return.